Vir Biotechnology, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage biopharmaceutical company that leverages immunology platforms to discover, develop and commercialize treatments for serious infectious diseases and oncology indications; its core technologies include a next-generation antibody platform and the PRO-XTEN protease-releasable masking technology exclusively licensed from Sanofi for oncology and infectious diseases. The company offers a deep pipeline of candidates such as tobevibart (an antibody incorporating Xencor's Xtend and other Fc technologies) combined with elebsiran for chronic hepatitis delta virus treatment in Phase 3 trials; VIR-5818, a dual-masked HER2-targeted T-cell engager in Phase 1 dose escalation with pembrolizumab for solid tumors; VIR-5500, a PSMA-targeted T-cell engager in Phase 1 with androgen receptor pathway inhibitors for prostate cancer; VIR-5525, an EGFR-targeted T-cell engager in Phase 1 monotherapy or with pembrolizumab; and preclinical efforts including undisclosed PRO-XTEN T-cell engagers, HIV cure antibodies with the Gates Foundation, and influenza A programs. Founded in 2016 and headquartered at 499 Illinois Street, Suite 500, in San Francisco, California, Vir Biotechnology operates primarily in the United States and Europe, targeting unmet needs in virology (hepatitis B/D, HIV, influenza, tuberculosis) and immuno-oncology with monoclonal antibodies, T-cell engagers, siRNA therapies and innate immunity modulators; it generates revenue from collaborations, grants and licenses. Recent developments include accelerated enrollment completion in the ECLIPSE 1 Phase 3 trial for hepatitis delta two months ahead of schedule, ongoing momentum in ECLIPSE 2 and 3 trials positioning for regulatory submissions, a planned comprehensive data update for influenza A candidate VIR-5500 in Q1 2026, expansion into first-line prostate cancer via a VIR-5500/ARPI combination study, a $250 million funding round at a $4.2 billion valuation bringing total raised to $821 million, and sustained strategic partnerships with GlaxoSmithKline, Alnylam Pharmaceuticals, Brii Biosciences, MedImmune and Sanofi to support pipeline advancement.
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity
Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000
Backer Marianne De Sells 72,559 Shares of Vir Biotechnology (NASDAQ:VIR) Stock
Vir Biotechnology, Inc. $VIR Shares Sold by Citigroup Inc.
Vir Biotechnology to Participate in Upcoming Investor Conferences
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
Vir Biotechnology Announces Proposed Public Offering of Common Stock
Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish
These Analysts Boost Their Forecasts On Vir Biotechnology